{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T22:51:34Z","timestamp":1791154294114,"version":"4.1.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Health Research Council New Zealand","award":["20-680"],"award-info":[{"award-number":["20-680"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"DOI":"10.1007\/s40261-026-01600-9","type":"journal-article","created":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T15:14:47Z","timestamp":1791040487000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Proton Pump Inhibitor Co-prescription, Dabigatran Use, and Ischaemic Stroke or Transient Ischaemic Attack in Atrial Fibrillation: A Population-Based Case-Control Study"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2256-6470","authenticated-orcid":false,"given":"Karim M.","family":"Mahawish","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valery","family":"Feigin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harvey","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Krishnamurthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,3]]},"reference":[{"key":"1600_CR1","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jacc.2023.08.017","volume":"83","author":"JA Joglar","year":"2023","unstructured":"Joglar JA, Chung MK, Armbruster AL, Benjamin EJ, Chyou JY, Cronin EM, et al. 2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation. J Am Coll Cardiol. 2023;83:109\u2013279. https:\/\/doi.org\/10.1016\/j.jacc.2023.08.017.","journal-title":"J Am Coll Cardiol"},{"key":"1600_CR2","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1111\/fcp.12154","volume":"29","author":"E Ollier","year":"2015","unstructured":"Ollier E, Hodin S, Basset T, Accassat S, Bertoletti L, Mismetti P, et al. In vitro and in vivo evaluation of drug\u2013drug interaction between dabigatran and proton pump inhibitors. Fundam Clin Pharmacol. 2015;29:604\u201314. https:\/\/doi.org\/10.1111\/fcp.12154.","journal-title":"Fundam Clin Pharmacol"},{"key":"1600_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-057991","volume":"12","author":"M Wang","year":"2022","unstructured":"Wang M, Paterson M, Thabane L, Siegal D, Mbuagbaw L, Targownik L, et al. Association of direct oral anticoagulant-proton pump inhibitor cotherapy with adverse outcomes: protocol for a population-based cohort study. BMJ Open. 2022;12:e057991. https:\/\/doi.org\/10.1136\/bmjopen-2021-057991.","journal-title":"BMJ Open"},{"key":"1600_CR4","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.jacc.2020.09.011","volume":"77","author":"DJ Kumbhani","year":"2020","unstructured":"Kumbhani DJ, Cannon CP, Beavers CJ, Bhatt DL, Cuker A, Gluckman TJ, et al. 2020 ACC expert consensus decision pathway for anticoagulant and antiplatelet therapy in patients with atrial fibrillation or venous thromboembolism undergoing percutaneous coronary intervention or with atherosclerotic cardiovascular disease. J Am Coll Cardiol. 2020;77:629\u201358. https:\/\/doi.org\/10.1016\/j.jacc.2020.09.011.","journal-title":"J Am Coll Cardiol"},{"key":"1600_CR5","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1111\/imj.15159","volume":"51","author":"KM Mahawish","year":"2021","unstructured":"Mahawish KM, Leung A. Failure of dabigatran following idarucizumab and omeprazole administration. Intern Med J. 2021;51:134\u20135. https:\/\/doi.org\/10.1111\/imj.15159.","journal-title":"Intern Med J"},{"key":"1600_CR6","doi-asserted-by":"publisher","first-page":"e308","DOI":"10.1097\/MJT.0000000000000599","volume":"26","author":"T Bolek","year":"2019","unstructured":"Bolek T, Samo\u0161 M, Stan\u010diakov\u00e1 L, Ivankov\u00e1 J, \u0160kor\u0148ov\u00e1 I, Sta\u0161ko J, et al. The impact of proton pump inhibition on dabigatran levels in patients with atrial fibrillation. Am J Ther. 2019;26:e308\u201313. https:\/\/doi.org\/10.1097\/MJT.0000000000000599.","journal-title":"Am J Ther"},{"key":"1600_CR7","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s00228-019-02647-8","volume":"75","author":"T Bolek","year":"2019","unstructured":"Bolek T, Samo\u0161 M, \u0160kor\u0148ov\u00e1 I, Schnierer M, Lipt\u00e1k P, B\u00e1nov\u010din P, et al. Dabigatran levels in omeprazole versus pantoprazole-treated patients with atrial fibrillation: is there a difference? Eur J Clin Pharmacol. 2019;75:875\u20137. https:\/\/doi.org\/10.1007\/s00228-019-02647-8.","journal-title":"Eur J Clin Pharmacol"},{"key":"1600_CR8","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.joa.2017.07.013","volume":"33","author":"T Kuwayama","year":"2017","unstructured":"Kuwayama T, Osanai H, Ajioka M, Tokuda K, Ohashi H, Tobe A, et al. Influence of proton pump inhibitors on blood dabigatran concentrations in Japanese patients with non\u2010valvular atrial fibrillation. J Arrhythm. 2017;33:619\u201323. https:\/\/doi.org\/10.1016\/j.joa.2017.07.013.","journal-title":"J Arrhythm"},{"key":"1600_CR9","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1097\/FJC.0000000000000791","volume":"75","author":"M Schnierer","year":"2020","unstructured":"Schnierer M, Samo\u0161 M, Bolek T, \u0160kor\u0148ov\u00e1 I, Nos\u00e1kov\u00e1 L, B\u00e1nov\u010din P, et al. The effect of proton pump inhibitor withdrawal on dabigatran etexilate plasma levels in patients with atrial fibrillation: a washout study. J Cardiovasc Pharmacol. 2020;75:333\u20135. https:\/\/doi.org\/10.1097\/FJC.0000000000000791.","journal-title":"J Cardiovasc Pharmacol"},{"key":"1600_CR10","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1007\/s00059-014-4188-9","volume":"40","author":"C St\u00f6llberger","year":"2015","unstructured":"St\u00f6llberger C, Finsterer J. Relevance of P-glycoprotein in stroke prevention with dabigatran, rivaroxaban, and apixaban. Herz. 2015;40:140\u20135. https:\/\/doi.org\/10.1007\/s00059-014-4188-9.","journal-title":"Herz"},{"key":"1600_CR11","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139\u201351. https:\/\/doi.org\/10.1056\/NEJMoa0905561.","journal-title":"N Engl J Med"},{"key":"1600_CR12","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1159\/000546212","volume":"60","author":"KM Mahawish","year":"2026","unstructured":"Mahawish KM, Zeng I, White H, Feigin V, Krishnamurthi R. Methods article for a study protocol: refining stroke prediction in atrial fibrillation patients in an ethnically diverse population \u2013 a study protocol. Neuroepidemiology. 2026;60:413\u201321. https:\/\/doi.org\/10.1159\/000546212.","journal-title":"Neuroepidemiology"},{"key":"1600_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2025.101508","volume":"56","author":"VL Feigin","year":"2025","unstructured":"Feigin VL, Krishnamurthi R, Nair B, Rautalin I, Parag V, Anderson CS, et al. Trends in stroke incidence, death, and disability outcomes in a multi-ethnic population: Auckland regional community stroke studies (1981\u20132022). Lancet Reg Health West Pac. 2025;56:101508. https:\/\/doi.org\/10.1016\/j.lanwpc.2025.101508.","journal-title":"Lancet Reg Health West Pac."},{"key":"1600_CR14","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1161\/STROKEAHA.116.014010","volume":"47","author":"PA Barber","year":"2011","unstructured":"Barber PA, Krishnamurthi R, Parag V, Anderson NE, Ranta A, Kilfoyle D, et al. Incidence of transient ischemic attack in Auckland, New Zealand, in 2011 to 2012. Stroke. 2011;47:2183\u20138. https:\/\/doi.org\/10.1161\/STROKEAHA.116.014010.","journal-title":"Stroke"},{"key":"1600_CR15","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1007\/s11239-019-01986-8","volume":"49","author":"A Prentice","year":"2020","unstructured":"Prentice A, Ruiz I, Weeda ER. Medication adherence to rivaroxaban and dabigatran in patients with non-valvular atrial fibrillation: a meta-analysis. J Thromb Thrombolysis. 2020;49:360\u20134. https:\/\/doi.org\/10.1007\/s11239-019-01986-8.","journal-title":"J Thromb Thrombolysis"},{"key":"1600_CR16","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","volume":"45","author":"IC Van Gelder","year":"2024","unstructured":"Van Gelder IC, Rienstra M, Bunting KV, Casado-Arroyo R, Caso V, Crijns HJGM, et al. 2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024;45:3314\u2013414. https:\/\/doi.org\/10.1093\/eurheartj\/ehae176.","journal-title":"Eur Heart J"},{"key":"1600_CR17","doi-asserted-by":"publisher","first-page":"W-163","DOI":"10.7326\/0003-4819-147-8-200710160-00010-w1","volume":"147","author":"JP Vandenbroucke","year":"2007","unstructured":"Vandenbroucke JP, von Elm E, Altman DG, G\u00f8tzsche PC, Mulrow CD, Pocock SJ, et al. Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. Ann Intern Med. 2007;147:W-163. https:\/\/doi.org\/10.7326\/0003-4819-147-8-200710160-00010-w1.","journal-title":"Ann Intern Med"},{"key":"1600_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s13019-024-03161-4","volume":"20","author":"M Shabil","year":"2025","unstructured":"Shabil M, Padhi BK, Khatib MN, Menon SV, Kaur M, Kumari M, et al. Risk of stroke associated with proton pump inhibitor use among individuals with and without pre-existing cardiovascular diseases: a systematic review and meta-analysis. J Cardiothorac Surg. 2025;20:107. https:\/\/doi.org\/10.1186\/s13019-024-03161-4.","journal-title":"J Cardiothorac Surg"},{"key":"1600_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0253310","volume":"16","author":"H-J Lee","year":"2021","unstructured":"Lee H-J, Kim H-K, Kim B-S, Han K-D, Park J-B, Lee H, et al. Risk of upper gastrointestinal bleeding in patients on oral anticoagulant and proton pump inhibitor co-therapy. PLoS ONE. 2021;16:e0253310. https:\/\/doi.org\/10.1371\/journal.pone.0253310.","journal-title":"PLoS ONE"},{"key":"1600_CR20","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1177\/10600280251337209","volume":"60","author":"M Wang","year":"2026","unstructured":"Wang M, Paterson JM, Nguyen F, Siegal DM, Targownik L, Holbrook AM. Association of direct oral anticoagulant-proton pump inhibitor co-therapy with adverse outcomes: a population-based cohort study. Ann Pharmacother. 2026;60:115\u201329. https:\/\/doi.org\/10.1177\/10600280251337209.","journal-title":"Ann Pharmacother"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01600-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-026-01600-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01600-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T22:01:48Z","timestamp":1791151308000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-026-01600-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,3]]},"references-count":20,"alternative-id":["1600"],"URL":"https:\/\/doi.org\/10.1007\/s40261-026-01600-9","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,3]]},"assertion":[{"value":"22 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"KMM conceptualised and designed the study, applied for ethics approval, collected the data, performed the statistical analysis, interpreted the results, and drafted the manuscript. RK contributed to study design, assisted with ethics approval and provided critical revision of the manuscript. VF contributed critical revision of the manuscript. HW contributed to clinical interpretation of the pharmacological and cardiovascular aspects of the study and critically revised the manuscript. All authors read and approved the final version and agree to be accountable for the work.","order":1,"name":"Ethics","label":"Author contributions","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported by the Health Research Council, New Zealand. The funder had no role in the design, data collection, data analysis, and reporting of this study. (HRC grant number 20-680).","order":2,"name":"Ethics","label":"Funding","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The data that support the findings of this study are not publicly available due to patient privacy and institutional data governance restrictions. Anonymised data may be made available from the corresponding author following a request outlining the proposed research purpose, subject to institutional data-governance and ethical approval. Requests should be directed to Dr Karim Mahawish (tyj9598@autuni.ac.nz). All methods used in the analysis are described in the manuscript.","order":3,"name":"Ethics","label":"Data Sharing and Data Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. This study has been approved by the Health and Disability Ethics Committee (HDEC) (ref: 2023 AM 9094) and Auckland University of Technology Ethics Committee (24\/4).","order":4,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The requirement for written informed consent was waived by the Auckland University of Technology Ethics Committee (24\/4) because this was a low-risk observational study using routinely collected clinical data.","order":5,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"KMM received a Health Research Council of New Zealand grant as part of his doctoral studies for this research. HW reports grant support paid to the institution and fees for serving on Steering Committees of the ODYSSEY trial from Sanofi and Regeneron Pharmaceuticals, the ISCHAEMIA and MINT study from the National Institutes of Health, the Librexia and AF and ACS studies from Janssen Research and Development LLC and the MK0616 Study from Merck Sharp & Dolme Ltd. The other authors declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.\n                      Consent for Publication\n                      Not applicable.","order":6,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":7,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"ChatGPT was used to improve manuscript readability.","order":8,"name":"Ethics","label":"AI USE","group":{"name":"EthicsHeading","label":"Declarations"}}]}}